Evaluation and Follow‑Up of Incidental Hepatosplenomegaly in Asymptomatic Adults

1. Initial Clinical Assessment

1.1 Laboratory Work‑up

• Liver function tests (AST, ALT, alkaline phosphatase, bilirubin, albumin) should be obtained to detect hepatocellular injury or cholestasis. – Hepatology guideline [1]
• Serum ceruloplasmin and 24‑hour urinary copper are indicated when Wilson disease is suspected, particularly in patients < 40 years with unexplained hepatomegaly. – Hepatology guideline [1]
• A complete blood count with differential is essential to identify cytopenias that may signal portal hypertension, hemolysis, or a hematologic malignancy. – Blood Society recommendation [2]

1.2 History and Physical Examination

• Targeted questioning for chronic liver disease risk factors (alcohol use, viral hepatitis exposure, metabolic syndrome, autoimmune disease) is advised. – American College of Radiology (ACR) guidance [3]
• Assessment for portal‑hypertension manifestations (ascites, variceal bleeding, encephalopathy) should be performed even when the patient appears asymptomatic. – Hepatology guideline [1]
• Examination for stigmata of chronic liver disease (spider angiomas, palmar erythema, jaundice, palpable splenomegaly) is recommended. – Hepatology guideline [1]

1.3 Consideration of Specific Etiologies

• When clinical features suggest lysosomal storage disorders, metabolic work‑up for storage disease should be pursued, especially in younger individuals. – Genetics in Medicine recommendation [4]
• Wilson disease may present solely with splenomegaly from subclinical cirrhosis; clinicians should not rely on symptom absence to exclude it. – Hepatology guideline [1]
• If hereditary hemorrhagic telangiectasia is suspected, Doppler ultrasound is the first‑line imaging modality and liver biopsy should be avoided due to bleeding risk. – Journal of Hepatology guidance [5]

2. Imaging Follow‑Up Strategy (American College of Radiology)

2.1 Patients without Focal Liver Lesions

• Doppler ultrasound is the cost‑effective first‑line study to evaluate liver echotexture, portal‑vein patency, flow direction, and spleen size. – ACR guidance [3]
• Transient elastography or MR elastography may be employed to stage fibrosis non‑invasively when chronic liver disease is suspected. – ACR guidance [3]
• Multiphase CT or MRI should be reserved for cases where ultrasound is technically limited (e.g., obesity, overlying bowel gas) or yields indeterminate findings. – ACR guidance [3]

2.2 Patients with Focal Liver Lesions ≥ 1 cm

• Multiphase contrast‑enhanced CT (arterial, portal‑venous, delayed phases) or contrast‑enhanced MRI (with and without hepatobiliary agents) are equivalent first‑line options for lesion characterization in patients with a normal liver and no known malignancy. – ACR imaging recommendations [6, 7, 8]
• MRI is preferred when available because it provides superior lesion characterization, detects premalignant nodules, and avoids ionizing radiation. – ACR guidance [3]
• In the presence of chronic liver disease, lesions should be evaluated using LI‑RADS criteria; both multiphase CT and MRI with hepatobiliary contrast are appropriate. – ACR / LI‑RADS guidance [7, 9, 3]
• Contrast‑enhanced ultrasound can characterize ~95 % of lesions overall and differentiate benign from malignant lesions in ~90 % of cases. – ACR evidence [7, 10]

2.3 Patients with Subcentimeter Focal Lesions (< 1 cm)

• If chronic liver disease is present, MRI (with and without contrast) or multiphase CT should be performed because lesions ≥ 10 mm require definitive HCC diagnosis per LI‑RADS. – ACR / LI‑RADS guidance [7, 9]
• When no chronic liver disease or malignancy history exists, observation with repeat imaging in 3–6 months is reasonable. – ACR recommendation [6]

3. Referral and Subspecialty Consultation

• Refer to hepatology for abnormal liver function tests, imaging evidence of cirrhosis, or suspicion of chronic liver disease. – ACR guidance [3]
• Refer to hematology for cytopenias, splenomegaly with lymphadenopathy, or concern for a lymphoproliferative disorder. – Blood Society recommendation [2]
• Refer to genetics/metabolic specialists when a lysosomal storage disease is suspected based on clinical or family history. – Genetics in Medicine recommendation [4]

4. Timeline for Follow‑Up

• Dedicated contrast‑enhanced imaging (multiphase CT or MRI) should be completed within 4–6 weeks when focal lesions are identified or initial laboratory results are abnormal. – ACR imaging timeline [6, 7]
• Subspecialty consultation (hepatology, hematology, genetics) should occur within 4–8 weeks based on the results of the initial work‑up. – ACR consultation timeline [3]

Imaging Evaluation and Management of Incidental Liver Masses in Young Patients

Imaging Modality Selection for Lesions ≥1 cm

• The American College of Radiology (ACR) rates multiphase contrast‑enhanced CT and contrast‑enhanced MRI as “usually appropriate” (rating 7‑9) and equivalent first‑line options for characterizing liver lesions ≥ 1 cm detected on ultrasound in patients with a normal liver and no known malignancy. [11][12]
• When both modalities are available, the ACR prefers contrast‑enhanced MRI (with and without IV contrast) because it provides superior tissue characterization, can detect premalignant nodules, and avoids ionizing radiation—particularly important in younger individuals. [11][13]12
• Multiphase contrast‑enhanced CT (arterial, portal‑venous, and delayed phases) is an acceptable alternative when MRI is unavailable, contraindicated, or technically limited. [11][12]

Role of Contrast‑Enhanced Ultrasound (CEUS)

• CEUS can correctly characterize approximately 95 % of liver lesions overall and distinguish benign from malignant lesions in about 90 % of cases, making it a viable option when CT or MRI are not immediately accessible. 11

Prevalence and Nature of Benign Focal Liver Lesions

• Benign focal liver lesions are present in up to 15 % of individuals, with cysts, hemangiomas, and focal nodular hyperplasia being the most common types. [14][13]
• Even among patients who have a known primary malignancy elsewhere, benign liver lesions unrelated to the malignancy are identified in nearly 30 % of cases. 13

Pitfalls and Recommended Practices in Imaging Interpretation

• Avoid assuming benignity solely based on patient age. While benign lesions predominate in young patients, entities such as hepatocellular adenoma with malignant potential, fibrolamellar hepatocellular carcinoma, and metabolic diseases can also present. The ACR emphasizes careful evaluation of these possibilities. [14][13]

• Do not use non‑contrast CT or single‑phase CT for lesion characterization. These protocols are insufficient for accurate assessment and will often necessitate repeat imaging with appropriate multiphase contrast techniques. [11][12]

• Apply LI‑RADS criteria for any patient with clinical or imaging features suggestive of chronic liver disease (even subclinical), as the differential diagnosis shifts toward hepatocellular carcinoma and dysplastic nodules. The ACR recommends this standardized reporting system to improve diagnostic consistency. [11][12]